clinical trial · NCT04535986
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Chronic Obstructive Pulmonary DiseaseEnsifentrinePlacebo
brief summary
The purpose of this study is to evaluate the efficacy and safety of ensifentrine in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
started
Sep 29, 2020
primary completion
Sep 12, 2022
completion
Dec 2, 2022
last updated
Nov 13, 2023
official title
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol